



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 7, 2010

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,819
Filing Date	06/12/2006
First Named Inventor	Dominique BOUREL
Art Unit	1644
Examiner Name	Illa I. Ouspenski
Attorney Docket Number	065691-0408

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A1	SHIELDS ET AL., "High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcγRn and Design of IgG1 Variants with Improved Binding to the FcγR," <i>Journal of Biological Chemistry</i> , Vol. 276, No. 9, pp. 6591-6604 (March 2, 2001).	
	A2	RANDAEV ET AL., "The Structure of a Human Type III Fcγ Receptor in Complex with Fc," <i>Journal of Biological Chemistry</i> , Vol. 276, No. 19, pp. 16469-16477 (May 11, 2001).	
	A3	RADAEVE ET AL., "Recognition of IgG by Fcγ Receptor," <i>Journal of Biological Chemistry</i> , Vol. 276, No. 19, pp. 16478-16483 (May 11, 2001).	
	A4	KRAPP ET AL., "Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural Integrity," <i>Journal of Molecular Biology</i> , Vol. 325, pp. 979-989 (2003).	
	A5	UMANA ET AL., "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity," <i>Nature Biotechnology</i> , Vol. 17, pp. 176-180 (February 1999).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/551,819
Date Submitted: January 7, 2010		Filing Date	06/12/2006
(use as many sheets as necessary)		First Named Inventor	Dominique BOUREL
		Art Unit	1644
		Examiner Name	Iliia I. Ouspenski
		Attorney Docket Number	065691-0408
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A6	MORITA ET AL., "Rpf2p, an Evolutionarily Conserved Protein, Interacts with Ribosomal Protein L11 and is Essential for the Processing of 27 SB Pre-rRNA to 25 S rRNA and the 60 S Ribosomal Subunit Assembly in <i>Saccharomyces cerevisiae</i> ," <i>Journal of Biological Chemistry</i> , Vol. 277, No. 32, pp. 28780-28786 (August 9, 2002).		
	A7	AMIGORENA ET AL., "Cytoplasmic Domain Heterogeneity and Functions of IgG Fc Receptors in B Lymphocytes," <i>Science</i> , Vol. 256, pp. 1808-1812 (26 June 1992).		
	A8	MIMURA ET AL., "Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding," <i>Journal of Biological Chemistry</i> , Vol. 276, No. 49, pp. 45539-45547 (December 7, 2001).		
	A9	KATO ET AL., "Structural Basis of the Interaction between IgG and Fcγ Receptors," <i>Journal of Molecular Biology</i> , Vol. 295, pp. 213-224 (2001).		
	A10	LUND ET AL., "Oligosaccharide-protein interactions in IgG can modulate recognition by Fcγ receptors," <i>The FASEB Journal</i> , Vol. 9, pp. 115-119 (January 1995).		
	A11	JEFFERIS ET AL., "Recognition sites on human IgG for Fcγ receptors: the role of glycosylation," <i>Immunology Letters</i> , Vol. 44, pp. 111-117 (1995).		
	A12	JONES ET AL., "Different Phenotypic Variants of the Mouse B Cell Tumor A20/2J are Selected by Antigen- and Mitogen-Triggered Cytotoxicity of L3T4-Positive, I-A Restricted T Cell Clones," <i>Journal of Immunology</i> , Vol. 136, No. 1, pp. 349-356 (January 1, 1986).		
	A13	MALBEC ET AL., "Negative Regulation of Hematopoietic Cell Activation and Proliferation by FcγRIIb," <i>Immunoreceptor Tyrosine-Based Inhibition Motifs</i> , M. Daéron and E. Vivier eds., Springer-Verlag, Berlin, Germany, pp. 13-27 (1999).		

Examiner Signature	/Iliia Ouspenski/	Date Considered	01/18/2010
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.